23 Jul, 2026
According to Straits Research, the global respiratory syncytial virus diagnostics market size was valued at $6.65 billion in 2025 and is projected to grow from $7.01 billion in 2026 to $10.89 billion by 2034, registering a CAGR of 5.68% during the forecast period 2026–2034.
The global respiratory syncytial virus diagnostics market is witnessing steady expansion due to the rising global burden of RSV infections among infants, older adults, and immunocompromised individuals, which has heightened the need for early and accurate detection. Increasing adoption of rapid molecular diagnostic technologies, such as point-of-care PCR assays, is further accelerating market growth by enabling clinicians to identify RSV quickly and improve case management during peak seasonal outbreaks. Additionally, growing integration of multiplex respiratory panels in hospitals and diagnostic centers supports efficient differentiation between RSV, influenza, and other viral pathogens, enhancing clinical decision-making and reducing unnecessary treatments.
However, the market continues to face restraints related to the high cost of advanced RSV molecular testing systems and the operational expenses associated with maintaining laboratory infrastructure. In many low-income regions, limited reimbursement coverage and insufficient diagnostic capacity hinder widespread adoption of innovative RSV testing solutions. Despite these challenges, key opportunities are emerging as RSV gains global attention due to the recent introduction of preventive vaccines and monoclonal antibodies, which are expected to increase screening volumes. Expansion of decentralized testing through affordable rapid antigen and molecular point-of-care devices offers strong growth potential in community settings and outpatient clinics.
sales@straitsresearch.com